MedTrace Logo

Expanded Access Program for Epcoritamab

NCT05733650 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2023-05-25

No results posted yet for this study

Summary

The purpose of this program is to provide investigational epcoritamab, an antibody also known as GEN3013 (DuoBody-CD3xCD20), in an expanded access setting for eligible patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) who have a high unmet medical need with no other treatment options. It is a requirement that patients do not qualify for an ongoing epcoritamab clinical program or are unable to participate due to logistical reasons.

Access to investigational epcoritamab can be requested by contacting [email protected].

Conditions

  • Large B-cell Lymphoma
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • High Grade B-cell Lymphoma (HGBCL)
  • Grade 3B Follicular Lymphoma

Interventions

BIOLOGICAL

Epcoritamab

Eligible patients will receive epcoritamab (28-day cycle) that will be administered as subcutaneous (SC) injections until disease progression, or one or more of the treatment discontinuation criteria are met.

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Genmab

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05733650 on ClinicalTrials.gov